450 related articles for article (PubMed ID: 34894344)
21. Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.
Kong L; Tang Y; Zhang X; Lu G; Yu M; Shi Q; Wu X
Ann Pharmacother; 2017 Nov; 51(11):970-975. PubMed ID: 28677407
[TBL] [Abstract][Full Text] [Related]
22. Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
Kays MB; Fleming MR; Cheatham SC; Chung EK; Juenke JM
Ann Pharmacother; 2014 Feb; 48(2):178-86. PubMed ID: 24259653
[TBL] [Abstract][Full Text] [Related]
23. Population Pharmacokinetics Analysis and Dosing Simulations Of Meropenem in Critically Ill Patients with Pulmonary Infection.
Lan J; Wu Z; Wang X; Wang Y; Yao F; Zhao BX; Wang Y; Chen J; Chen C
J Pharm Sci; 2022 Jun; 111(6):1833-1842. PubMed ID: 35090867
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
[TBL] [Abstract][Full Text] [Related]
25. Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients.
Chung EK; Fleming MR; Cheatham SC; Kays MB
Ann Pharmacother; 2017 Mar; 51(3):209-218. PubMed ID: 28168884
[TBL] [Abstract][Full Text] [Related]
26. Optimization of β-Lactam Dosing Regimens in Neonatal Infections: Continuous and Extended Administration versus Intermittent Administration.
Leegwater E; Wewerinke L; de Grauw AM; van Veen M; Storm BN; Kruizinga MD
Clin Pharmacokinet; 2023 May; 62(5):715-724. PubMed ID: 36972008
[TBL] [Abstract][Full Text] [Related]
27. Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis.
Pařízková RČ; Martínková J; Havel E; Šafránek P; Kaška M; Astapenko D; Bezouška J; Chládek J; Černý V
Crit Care; 2021 Jul; 25(1):251. PubMed ID: 34274013
[TBL] [Abstract][Full Text] [Related]
28. Population Pharmacokinetic Modeling Using Polymyxin B Free Plasma Concentrations From Published Reports and Evaluation of Dosage Regimens Based on Monte Carlo Simulation in Critically Ill Patients.
Zheng Y; Xu B; Chen S; Liu M; Huang H; Wang J; Wu X
J Clin Pharmacol; 2023 Sep; 63(9):1036-1044. PubMed ID: 37125471
[TBL] [Abstract][Full Text] [Related]
29. Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients.
Zhao YC; Zou Y; Xiao YW; Wang F; Zhang BK; Xiang DX; Yu F; Luo H; Sandaradura I; Yan M
Infect Dis Ther; 2022 Feb; 11(1):201-216. PubMed ID: 34748194
[TBL] [Abstract][Full Text] [Related]
30. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
Sumitani Y; Kobayashi Y
Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation.
Idoate Grijalba AI; Aldaz Pastor A; Marquet P; Woillard JB
Eur J Clin Pharmacol; 2019 Oct; 75(10):1405-1414. PubMed ID: 31338539
[TBL] [Abstract][Full Text] [Related]
32. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis.
Brill MJ; Houwink AP; Schmidt S; Van Dongen EP; Hazebroek EJ; van Ramshorst B; Deneer VH; Mouton JW; Knibbe CA
J Antimicrob Chemother; 2014 Mar; 69(3):715-23. PubMed ID: 24214905
[TBL] [Abstract][Full Text] [Related]
33. Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model.
Minichmayr IK; Roberts JA; Frey OR; Roehr AC; Kloft C; Brinkmann A
J Antimicrob Chemother; 2018 May; 73(5):1330-1339. PubMed ID: 29425283
[TBL] [Abstract][Full Text] [Related]
34. Meropenem Plasma and Interstitial Soft Tissue Concentrations in Obese and Nonobese Patients-A Controlled Clinical Trial.
Simon P; Petroff D; Busse D; Heyne J; Girrbach F; Dietrich A; Kratzer A; Zeitlinger M; Kloft C; Kees F; Wrigge H; Dorn C
Antibiotics (Basel); 2020 Dec; 9(12):. PubMed ID: 33371322
[TBL] [Abstract][Full Text] [Related]
35. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
[TBL] [Abstract][Full Text] [Related]
36. Continuous infusion of piperacillin-tazobactam significantly improves target attainment in children with cancer and fever.
Maarbjerg SF; Thorsted A; Friberg LE; Nielsen EI; Wang M; Schrøder H; Albertsen BK
Cancer Rep (Hoboken); 2022 Oct; 5(10):e1585. PubMed ID: 34796702
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics and pharmacodynamics of cefazolin using total and unbound serum concentrations in patients with high body weight.
Chung EK; Cheatham SC; Healy DP; Stock AH; Utley S; Campion M; Murrey T; Gesenhues AM; Jeffery J; Kays MB
Int J Antimicrob Agents; 2023 Apr; 61(4):106751. PubMed ID: 36758780
[TBL] [Abstract][Full Text] [Related]
38. Is continuous infusion of imipenem always the best choice?
Suchánková H; Lipš M; Urbánek K; Neely MN; Strojil J
Int J Antimicrob Agents; 2017 Mar; 49(3):348-354. PubMed ID: 28189734
[TBL] [Abstract][Full Text] [Related]
39. Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations.
Charoensareerat T; Chaijamorn W; Kerdnimith P; Kosumwisaisakul N; Teeranaew P; Rungkitwattanakul D; Boonpeng A; Srisawat N; Pattharachayakul S
Blood Purif; 2023; 52(6):503-515. PubMed ID: 37231811
[TBL] [Abstract][Full Text] [Related]
40. Prophylactic Cefazolin Dosing in Women With Body Mass Index >35 kg·m-2 Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid.
Eley VA; Christensen R; Ryan R; Jackson D; Parker SL; Smith M; van Zundert AA; Wallis SC; Lipman J; Roberts JA
Anesth Analg; 2020 Jul; 131(1):199-207. PubMed ID: 32250982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
